<- Go Home

Craneware plc

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospective charge capture analytical application; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit solution for government and commercial payors. It also offers Trisus Decision Support; Trisus Labor Productivity, which enables healthcare providers to manage, analyze, and plan the deployment of workforce; Trisus Medication Analytic solutions that prioritize, diagnose, and resolve issues in medication systems; and Trisus supplies assistant solutions which supplies charged data. In addition, the company provides Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentinel, that tracks all drug activity; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, it offers professional, pharmacy professional, and appeal services. Additionally, the company provides The Academy, an interactive learning center for user training; Trisus Pricing Integrity Suite; Trisus Business of Pharmacy Suite, which offers solutions centered on each link in the medication revenue cycle; Trisus Value-based Margin and Productivity Suite; and Trisus Data Integrity Suite, which creates a proactive workflow that aligns data between operating units, the supply chain and revenue cycle. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.

Market Cap

GBP 942.6M

Volume

100.6K

Cash and Equivalents

GBP 72.2M

EBITDA

GBP 41.4M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

GBP 171.0M

Profit Margin

86.33%

52 Week High

GBP 33.98

52 Week Low

GBP 20.32

Dividend

1.36%

Price / Book Value

2.86

Price / Earnings

63.36

Price / Tangible Book Value

-9.40

Enterprise Value

GBP 906.3M

Enterprise Value / EBITDA

21.22

Operating Income

GBP 23.0M

Return on Equity

4.55%

Return on Assets

2.52

Cash and Short Term Investments

GBP 72.2M

Debt

GBP 35.9M

Equity

GBP 329.1M

Revenue

GBP 198.1M

Unlevered FCF

GBP 62.0M

Sector

Health Care Technology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches